StrokeRAGT_RGBNCT07529054
The Potential of Robotic-Assisted Gait Training in a Rehabilitation Setting
A study testing Lokomat + Vibramoov and Lokomat in people with Stroke and Robotic Assisted Gait Training, run by Ludwig Boltzmann Institute for Arthritis and Rehabilitation at 1 site in Austria.
Trial summary
Robotic-assisted gait training (RAGT) devices, such as the Lokomat®, are commonly used to support gait rehabilitation by enabling repetitive, task-specific walking movements. The functional proprioceptive stimulation (FPS) device Vibramoov® represents a novel technology designed to stimulate proprioceptors at the… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Stroke, Robotic Assisted Gait Training, Vibration Therapy
- What is being tested?
- Lokomat + Vibramoov and Lokomat
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteAustria
- Study dates
- 5 Jan 2026to Dec 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of stroke (ischemic or hemorrhagic) ≥ 3 months
- Age ≥ 18a and ≤ 80a
- 6MWT ≤ 200m
- Barthel Index ≤ 95
- Mini Mental State Exam (MMSE) ≥ 24
- FAC: ≤ 4
- BBS): ≤49
- Modified Ashworth Scale (MAS): 0-3 for the lower extremity
Who cannot join
- The presence of any comorbidity or disability other than stroke that would preclude gait training
- Any uncontrolled health condition for which exercise is contraindicated
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Austria1 site, 1 recruiting
- Recruiting
Reha-Zentrum Gröbming
Gröbming, Styria, 8962
About this study
Official title: The Potential of Robotic-Assisted Gait Training in a Rehabilitation Settin
Robotic-assisted gait training (RAGT) devices, such as the Lokomat®, are commonly used to support gait rehabilitation by enabling repetitive, task-specific walking movements. The functional proprioceptive stimulation (FPS) device Vibramoov® represents a novel technology designed to stimulate proprioceptors at the muscle-tendon junction through targeted vibratory stimuli, thereby activating sensorimotor centers in the brain and potentially facilitating movement execution.
The aim of this randomized controlled trial is to investigate whether Lokomat® training combined with Vibramoov® leads to greater improvements in qualitative and quantitative gait parameters in stroke patients compared with Lokomat® training alone. The study will be conducted at the Gröbming Rehabilitation Center and will include patients undergoing a four-week neurological inpatient rehabilitation program. Participants will be randomly assigned to an intervention group (Lokomat® + Vibramoov®) or a control group (Lokomat® only), with 20 patients per group.
Primary outcomes include the 6-Minute Walk Test (6MWT) and spatiotemporal gait parameters. Additional assessments include functional scores, patient-reported outcome measures, and blood biomarkers. Statistical analyses will be performed depending on data distribution. A follow-up assessment evaluating EQ-5D and PHQ-4 will be conducted six months after completion of the rehabilitation program.
Read the detailed description
Stroke is the most common cause of physical disability in Western industrialized countries, with approximately 70% of patients experiencing moderate to severe physical impairments [1]. In addition to the negative impact on mobility and balance, activities of daily living are often affected [2]. In particular, gait impairments-manifested, for example, by reduced walking speed or shortened step length-can significantly reduce the quality of life of patients after stroke [2,3]. Therefore, the restoration of a physiological gait pattern in terms of both qualitative and quantitative parameters represents a key objective of post-stroke rehabilitation.
In addition to conventional therapeutic approaches, robotic-assisted gait training (RAGT) devices such as the Lokomat® are frequently used [4]. With this device, patients are able to walk actively on a treadmill while being supported by an exoskeleton that simulates a symmetrical, bilateral gait pattern [3]. RAGT devices aim to improve walking by enabling a high number of repetitions of task-oriented movements, thereby facilitating the relearning of movement patterns [5].
Novel technologies such as the functional proprioceptive stimulation (FPS) device Vibramoov® may have the potential to enhance the effectiveness of RAGT. This therapeutic device aims to stimulate proprioceptors located at the muscle-tendon junction through targeted vibratory stimuli, thereby activating sensorimotor centers in the brain via afferent Ia fibers [6]. As a result, the execution of movements-for example during walking-may be facilitated. According to the manufacturer, Vibramoov® can be used during walking on level ground, during treadmill walking, or in combination with the Lokomat®. However, to date there is no research investigating the effects of Vibramoov® on gait parameters in stroke patients undergoing inpatient rehabilitation.
The aim of the present study is therefore to contribute to the investigation of FPS as a potential approach to maximize the effectiveness of RAGT. The primary research question is: Does Lokomat® training combined with the Vibramoov® device have a greater effect on qualitative and quantitative gait parameters in patients after stroke compared with Lokomat® training alone? To address this research question, a randomized controlled trial will be conducted at the Gröbming Rehabilitation Center. Patients after stroke who are undergoing a four-week neurological inpatient rehabilitation program will be randomly assigned to either an intervention group or a control group. Based on data regarding the effect of RAGT on the 6-Minute Walk Test (6MWT), and accounting for potential dropouts, a sample size of 20 patients per group was calculated [4].
Patients in both groups will receive the conventional rehabilitation program according to the medical service profile, in which RAGT represents part of the standard treatment for stroke patients with gait impairments. Patients in the control group will perform RAGT using the Lokomat®, while patients in the intervention group will perform RAGT using the Lokomat® in combination with Vibramoov®. The extent of RAGT will be identical in both groups.
The effects of the intervention will be quantified using several outcome parameters, including the 6-Minute Walk Test (6MWT) and spatiotemporal gait parameters. In addition, various functional scores and patient-reported outcome measures will be collected, and laboratory parameters and blood biomarkers will be analyzed. Depending on the distribution of the data, standard statistical methods such as the independent t-test or the Mann-Whitney U test will be applied to address the research question. A follow-up assessment six months after completion of the study (telephone interview) evaluating EQ-5D and PHQ-4 is planned.
- Being tested
- Lokomat + Vibramoov, Lokomat
- Keywords
- Robotic Assisted Gait Training, Functional Proprioceptive Stimulation, Gait Parameter
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lokomat + VibramoovDevice
The conventional Robotic Assisted Gait Training is combined with vibrational stimuli which is a novel approach.
LokomatDevice
Conventional Robotic Assisted Gait Training with the Lokomat
| Study group | Role | What they receive |
|---|---|---|
| Lokomat + Vibramoov | Experimental | Patients in the interventional group receive RAGT (Lokomat) combined with vibrational stimuli (Vibramoov). Additionally they receive the standard rehabiliation procedure. Receives: Device: Lokomat + Vibramoov |
| Lokomat | Active comparator | Patients in the interventional group receive the conventional RAGT (Lokomat) without vibrational stimuli (Vibramoov). Additionally they receive the standard rehabiliation procedure. Receives: Device: Lokomat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Spatio Temporal Gait Parameter (STGP)
STGP, such as cadence or step lenght measured in a clinical gait analysis by a pressure measuring plate.
Measured: At baseline and 4 weeks later after intervention
6 Minute Walk Test (6MWT)
The 6MWT is a simple functional exercise test used to assess a person's walking capacity and endurance. It measures the distance a patient can walk in six minutes on a flat surface and reflects their submaximal level of functional capacity.
Measured: At baseline and 4 weeks later after intervention
Secondary outcomes (6)
Brain Derived Neurotrophic Factor (BDNF)
Biomarker measured in the serum, which is an indicator of the amount of neuroplasticity in the central nervous system.
Measured: At baseline and 4 weeks later after intervention
Routine Laboratory Parameter
Routine laboratory parameter, such as inflammatory markers measured in the serum.
Measured: At baseline and 4 weeks later after intervention
Berg Balance Scale
Assessment for evaluation of balance and risk of falls.
Measured: At baseline and 4 weeks later after intervention
Functional Ambulation Category (FAC)
FAC is a clinical scale used to assess a patient's walking ability and level of assistance required for ambulation.
Measured: At baseline and 4 weeks later after intervention
Patient Health Questionnaire-4 (PHQ-4)
The PHQ-4 is a brief screening questionnaire for anxiety and depression.
Measured: At baseline and 4 weeks later after intervention
European Quality of Life 5 Dimensions (EQ-5D)
The EQ-5D is a standardized questionnaire used to measure health-related quality of life.
Measured: At baseline and 4 weeks later after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2026
- Study start5 Jan 2026
- Primary completionFeb 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomized to either the control group or the intervention group. To ensure a balanced distribution between groups, a minimization approach considering four stratification factors-age, sex, spasticity, and stroke phase-is used.
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ludwig Boltzmann Institute for Arthritis and Rehabilitation
- Sponsor type
- Research network
- Collaborators
- Reha-Zentrum Gröbming
- Responsible party
- Sponsor
- Investigators
- Bibiane Steinecker-Frohnwieser, Priv. Doz. Mag. Dr., Study director, Ludwig Boltzmann Institut Arthritis und Rehabilitation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07529054
- Sponsor's protocol ID
- LudwigBoltzmannAR
- Acronym
- RAGT_RGB
- Status last verified
- Apr 2026
- First submitted
- 7 Apr 2026
- Last updated
- 14 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
[1] D. Calafiore, F. Negrini, N. Tottoli, F. Ferraro, O. Ozyemisci-Taskiran, und A. de Sire, "Efficacy of robotic exoskeleton for gait rehabilitation in patients with subacute stroke : a sys-tematic review", Eur J Phys Rehabil Med, Bd. 58, Nr. 1, S. 1-8, Feb. 2022, doi: 10.23736/S1973-9087.21.06846-5. [2] L. Wu, G. Xu, und Q. Wu, "The effect of the Lokomat® robotic-orthosis system on lower extremity rehabilitation in patients with stroke: a systematic review and meta-analysis", Front Neurol, Bd. 14, S. 1260652, 2023, doi: 10.3389/fneur.2023.1260652. [3] F. Baronchelli, C. Zucchella, M. Serrao, D. Intiso, und M. Bartolo, "The Effect of Robot-ic Assisted Gait Training With Lokomat® on Balance Control After Stroke: Systematic Review and Meta-Analysis", Front. Neurol., Bd. 12, Juli 2021, doi: 10.3389/fneur.2021.661815. [4] R. Mustafaoglu, B. Erhan, I. Yeldan, B. Gunduz, und E. Tarakci, "Does robot-assisted gait training improve mobility, activities of daily living and quality of life in stroke? A single-blinded, randomized controlled trial", Acta Neurol Belg, Bd. 120, Nr. 2, S. 335-344, Apr. 2020, doi: 10.1007/s13760-020-01276-8. [5] C. Schneider u. a., "Disentangling the percepts of illusory movement and sensory stimulation during tendon vibration in the EEG", NeuroImage, Bd. 241, S. 118431, Nov. 2021, doi: 10.1016/j.neuroimage.2021.118431. [6] R. S. Calabrò u. a., "Shaping neuroplasticity by using powered exoskeletons in pa-tients with stroke: a randomized clinical trial", J NeuroEngineering Rehabil, Bd. 15, Nr. 1, S. 35, Dez. 2018, doi: 10.1186/s12984-018-0377-8.